Peptides clinical practice

PT-141 — Sexual Wellness (FDA Standard)

Bremelanotide (PT-141) FDA-approved as-needed treatment for hypoactive sexual desire disorder in premenopausal women (Vyleesi). Used off-label in all genders for libido enhancement. Melanocortin receptor agonist — central mechanism, not vascular.

Duration

—

Steps

1

Total Weeks

—

Route

SubQ

Protocols

1

Source

clinical practice

Protocol Timeline

Step Weeks Dose Compound Note
1 0 1.75 mg PT-141 (Bremelanotide) Max 1 dose/24h, max 8/month. 45+ min before activity.

Rationale

Administer 45–60 minutes before anticipated sexual activity. FDA dose: 1.75mg SubQ. Community often uses 0.5–1mg to reduce nausea side effect. Transient nausea, flushing, and blood pressure increase are common. Do not use more than once every 24 hours.

Compounds Used

PT-141 (Bremelanotide)

pt_141 · primary

→

Related Tools

Medication Level Plotter

Simulate blood levels for this regimen

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide weekly totals into multiple injections

Track this regimen in Doseline

Adopt PT-141 — Sexual Wellness (FDA Standard) as a template, set reminders for every step, and log doses as you go. All free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.